NCT07178145View on ClinicalTrials.gov

Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

December 31, 2029

Conditions
Heart Failure Preserved Ejection FractionEpicardial Adipose Tissue
Interventions
DRUG

GLP-1RA

Receive 6 months of GLP-1RA (Semaglutide) treatment starting at 0.25mg once weekly and then the dose will be up titrated as tolerated every four weeks to once-weekly doses of 0.5, 1.0, 1.7, and 2.4 mg until a target dose of 2.4mg is reached after 16 weeks.

Trial Locations (1)

22903

University of Virginia, Charlottesville

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of Virginia

OTHER